Eric Raymond

Summary

Country: France

Publications

  1. ncbi request reprint Current development of mTOR inhibitors as anticancer agents
    Sandrine Faivre
    Service Inter Hospitalier de Cancrologie, Beaujon University Hospital, 100 Boulevard du General Leclerc, 92118 Clichy Cedex, France
    Nat Rev Drug Discov 5:671-88. 2006
  2. doi request reprint Sunitinib malate for the treatment of pancreatic neuroendocrine tumors
    Eric Raymond
    Service Inter Hospitalier de Cancérologie et Service de Gastroenteropancréatologie, Hopital Beaujon, Clichy, France
    N Engl J Med 364:501-13. 2011
  3. doi request reprint A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors
    E Raymond
    Service Inter Hospitalier de Cancérologie Beaujon Bichat, Hopital Beaujon, Clichy, France
    Invest New Drugs 32:94-103. 2014
  4. pmc Mechanisms of action of tasquinimod on the tumour microenvironment
    E Raymond
    Department of Medical Oncology, Beaujon University Hospital, Clichy, France
    Cancer Chemother Pharmacol 73:1-8. 2014
  5. pmc Predictive factors of sensitivity to elisidepsin, a novel Kahalalide F-derived marine compound
    Maria Serova
    AAREC Filia Research, 1, Paul Verlaine, Boulogne Billancourt 92100, France
    Mar Drugs 11:944-59. 2013
  6. doi request reprint Sunitinib in pancreatic neuroendocrine tumors
    Eric Raymond
    Department of Medical Oncology INSERM U728 Paris 7 Diderot University, Beaujon University Hospital, 100 Boulevard du General Leclerc, 92110, Clichy, France
    Target Oncol 7:117-25. 2012
  7. pmc Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib
    Charles S Harmon
    Pfizer Oncology, La Jolla, CA, USA
    J Transl Med 9:120. 2011
  8. doi request reprint Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors
    Eric Raymond
    Medical Oncology Department, Beaujon University Hospital, INSERM U728, APHP, Paris 7 University, 100 bd du Général Leclerc, 92880, Clichy, France
    Cancer Metastasis Rev 30:19-26. 2011
  9. doi request reprint Sunitinib paves the way for targeted therapies in neuroendocrine tumors
    Eric Raymond
    Department of Medical Oncology and Gastroenterology, Beaujon University Hospital, Clichy, France
    Target Oncol 4:253-4. 2009
  10. doi request reprint Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies
    Annemilaï Tijeras-Raballand
    Pre clinical Department, AAREC Filia Research, Boulogne Billancourt, France
    Target Oncol 7:173-81. 2012

Detail Information

Publications52

  1. ncbi request reprint Current development of mTOR inhibitors as anticancer agents
    Sandrine Faivre
    Service Inter Hospitalier de Cancrologie, Beaujon University Hospital, 100 Boulevard du General Leclerc, 92118 Clichy Cedex, France
    Nat Rev Drug Discov 5:671-88. 2006
    ..Here we review the clinical development of this drug class and look at future prospects for incorporating these agents into multitarget or multimodality strategies against cancer...
  2. doi request reprint Sunitinib malate for the treatment of pancreatic neuroendocrine tumors
    Eric Raymond
    Service Inter Hospitalier de Cancérologie et Service de Gastroenteropancréatologie, Hopital Beaujon, Clichy, France
    N Engl J Med 364:501-13. 2011
    ..The multitargeted tyrosine kinase inhibitor sunitinib has shown activity against pancreatic neuroendocrine tumors in preclinical models and phase 1 and 2 trials...
  3. doi request reprint A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors
    E Raymond
    Service Inter Hospitalier de Cancérologie Beaujon Bichat, Hopital Beaujon, Clichy, France
    Invest New Drugs 32:94-103. 2014
    ..MSC1992371A is an aurora kinase inhibitor with potential antitumor activity...
  4. pmc Mechanisms of action of tasquinimod on the tumour microenvironment
    E Raymond
    Department of Medical Oncology, Beaujon University Hospital, Clichy, France
    Cancer Chemother Pharmacol 73:1-8. 2014
    ..Based on its unique combination of effects, tasquinimod is a novel agent with clinical therapeutic potential in various solid tumours, both alone and as part of rational combination therapy. ..
  5. pmc Predictive factors of sensitivity to elisidepsin, a novel Kahalalide F-derived marine compound
    Maria Serova
    AAREC Filia Research, 1, Paul Verlaine, Boulogne Billancourt 92100, France
    Mar Drugs 11:944-59. 2013
    ..Combinations of elisidepsin with lapatinib and several chemotherapies including 5-FU and oxaliplatin resulted in synergistic effects that offer the potential of clinical use of elisidepsin in combination settings...
  6. doi request reprint Sunitinib in pancreatic neuroendocrine tumors
    Eric Raymond
    Department of Medical Oncology INSERM U728 Paris 7 Diderot University, Beaujon University Hospital, 100 Boulevard du General Leclerc, 92110, Clichy, France
    Target Oncol 7:117-25. 2012
    ..The optimal sequence for using chemotherapy, everolimus, and sunitinib will remain to be established in clinical trials...
  7. pmc Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib
    Charles S Harmon
    Pfizer Oncology, La Jolla, CA, USA
    J Transl Med 9:120. 2011
    ..In a phase II study of sunitinib in advanced HCC, we evaluated the plasma pharmacodynamics of five proteins related to the mechanism of action of sunitinib and explored potential correlations with clinical outcome...
  8. doi request reprint Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors
    Eric Raymond
    Medical Oncology Department, Beaujon University Hospital, INSERM U728, APHP, Paris 7 University, 100 bd du Général Leclerc, 92880, Clichy, France
    Cancer Metastasis Rev 30:19-26. 2011
    ..This review updates the results of ongoing trials using inhibitors of growth factors and tyrosine kinase receptors involved in the carcinogenesis of GEP-NETs...
  9. doi request reprint Sunitinib paves the way for targeted therapies in neuroendocrine tumors
    Eric Raymond
    Department of Medical Oncology and Gastroenterology, Beaujon University Hospital, Clichy, France
    Target Oncol 4:253-4. 2009
    ..In addition, other drugs with distinct mechanisms of action, such as mTOR inhibitors, currently investigated in phase III trials, may also supply novel options in those diseases to control tumor growth and metastasis...
  10. doi request reprint Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies
    Annemilaï Tijeras-Raballand
    Pre clinical Department, AAREC Filia Research, Boulogne Billancourt, France
    Target Oncol 7:173-81. 2012
    ..Overcoming such resistances is likely to be the next challenge for clinicians in advanced PNETs management, warranting seeking for new anticancer strategies...
  11. doi request reprint Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase Cbeta inhibitor enzastaurin in colon cancer cells
    Maria Serova
    INSERM U728, RayLab, Beaujon University Hospital AP HP Paris 7 Diderot, Clichy, France
    Mol Cancer Ther 9:1308-17. 2010
    ..From this study, colon cancer cells undergoing apoptosis under enzastaurin exposure seem to frequently express a WT Ras and an epithelial phenotype...
  12. doi request reprint Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib
    Maria Serova
    AAREC Filia Research, 1 place Paul Verlaine, 92100 Boulogne Billancourt, France
    Cancer Chemother Pharmacol 71:1297-307. 2013
    ....
  13. pmc FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts
    Cindy Neuzillet
    Service de Gastroentérologie Pancréatologie, Hopital Beaujon, 100 Boulevard du General Leclerc, 92110 Clichy La Garenne, AP HP, France
    World J Gastroenterol 18:4533-41. 2012
    ..To evaluate the efficacy and safety of the FOLFIRI regimen in patients with metastatic pancreatic adenocarcinoma (PAC) after the failure of gemcitabine and platinum salts...
  14. doi request reprint Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib
    Sandrine Faivre
    Department of Medical Oncology, Beaujon University Hospital AP HP Paris 7 Diderot, Clichy, France
    Target Oncol 7:127-33. 2012
    ....
  15. doi request reprint Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib
    Sandrine Faivre
    Beaujon University Hospital, Clichy, France
    Clin Cancer Res 17:4504-12. 2011
    ..This exploratory analysis investigated tumor density as a surrogate endpoint of sunitinib activity in a phase II HCC study...
  16. doi request reprint New treatment options with cytotoxic agents in neuroendocrine tumours
    Pascal Hammel
    Service de Gastroentérologie Pancréatologie, Hopital Beaujon, AP HP, Faculté Denis Diderot Paris VII, Clichy, France
    Target Oncol 7:169-72. 2012
    ..Careful attention should be paid to the adverse events in order to maintain the quality of life in these patients who have with a long life expectancy...
  17. doi request reprint Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development
    Marie Paule Sablin
    U Inserm Université Paris VII, Hopital Beaujon, Paris, France
    Expert Opin Drug Metab Toxicol 6:1005-15. 2010
    ..Sunitinib belongs to the category of new drugs that inhibit multityrosine kinase receptors involved in the key steps of tumorigenesis and angiogenesis...
  18. doi request reprint Is adjuvant therapy with streptozotocin and 5-fluorouracil useful after resection of liver metastases from digestive endocrine tumors?
    Frédérique Maire
    Pôle des Maladies de l Appareil Digestif, Service de Gastroentérologie Pancréatologie, Hopital Beaujon, Clichy, France
    Surgery 145:69-75. 2009
    ..However, 5-year recurrence occurs in 50-80% of patients in the literature. The effect of adjuvant chemotherapy (CT) on relapse-free survival (RFS) and overall survival (OS) is unknown...
  19. doi request reprint Novel molecular therapies in hepatocellular carcinoma
    Sandrine Faivre
    Department of Medical Oncology, Beaujon Bichat University Hospital, Assistance Publique Hopitaux de Paris, University INSERM U728, Paris 7, Clichy, France
    Liver Int 31:151-60. 2011
    ..Currently published data suggest that substantial progress may be achieved in the treatment of patients with HCC in the next 10 years...
  20. doi request reprint Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors
    Sandrine Faivre
    Department of Medical Oncology, Beaujon University Hospital AP HP, Paris 7 Diderot, Clichy, France
    Endocrinol Metab Clin North Am 39:811-26. 2010
    ..Based on recent data, novel strategies may now be designed using those anticancer agents to optimize the current treatment of patients with NETs...
  21. doi request reprint Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma
    Hélène Marijon
    Department of Medical Oncology APHP, Beaujon University Hospital, Paris 7 Diderot, Clichy, France
    J Hepatol 54:1073-8. 2011
    ..Herein, we report translational data from a post-treatment surgical specimen in a patient who experienced acquired resistance to sunitinib...
  22. pmc Gemcitabine in elderly patients with advanced pancreatic cancer
    Olivia Hentic
    Pôle des Maladies de l Appareil Digestif, Service de Pancréatologie, Hopital Beaujon, 100 Boulevard du General Leclerc, 92110 Clichy, France
    World J Gastroenterol 17:3497-502. 2011
    ..To assess feasibility, tolerability and efficacy of gemcitabine-based chemotherapy in patients ≥ 75 years old with advanced pancreatic cancer...
  23. doi request reprint Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors
    Catherine Delbaldo
    Paris Nord Val de Seine University Hospitals, Clichy, Paris, France
    Target Oncol 6:119-24. 2011
    ..Translational research aimed at validating those parameters in clinical trials is ongoing...
  24. doi request reprint Targeting the Ras-ERK pathway in pancreatic adenocarcinoma
    Cindy Neuzillet
    INSERM U728 and Department of Medical Oncology, Beaujon University Hospital AP HP Paris 7 Diderot, Clichy, France
    Cancer Metastasis Rev 32:147-62. 2013
    ..In this review, we describe the role of the Ras-ERK pathway in pancreatic carcinogenesis and as a new therapeutic target for the treatment of PAC...
  25. doi request reprint Focus on the role of the CXCL12/CXCR4 chemokine axis in head and neck squamous cell carcinoma
    Sebastien Albert
    INSERM U728, RayLab, and Departments of Medical Oncology, Beaujon University Hospital AP HP, Paris 7 Diderot, Clichy, France Department of Head and Neck Surgery, Bichat University Hospital, Paris, France
    Head Neck 35:1819-28. 2013
    ..Furthermore, knowledge of the role of CXCR4 in HNSCC could influence the development of new targeted therapies for treatment, aimed at improving the prognosis of this disease...
  26. doi request reprint [Targeted therapies in hepatocellular carcinoma]
    Mohamed Bouattour
    Service inter hospitalier de cancérologie Bichat Beaujon, Hopital Beaujon, 92110 Clichy, France
    Presse Med 39:753-64. 2010
    ..This review summarizes the results of clinical trials in which targeted therapies are currently evaluated aiming to enlarge the therapeutic armamentarium for HCC in a near future...
  27. doi request reprint Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies
    Christophe Le Tourneau
    Department of Medical Oncology, Beaujon University Hospital, Paris 7, AP HP, Clichy, France
    Eur J Cancer 46:3243-50. 2010
    ..Phase I study of seliciclib (CYC202, R-roscovitine), an inhibitor of cyclin-dependent kinases 2, 7 and 9, causing cell cycle changes and apoptosis in cancer cells...
  28. doi request reprint Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells
    Aida Ghoul
    Institut National de la Sante et de la Recherche Medicale U728, RayLab, and Department of Medical Oncology, Beaujon and Saint Louis University Hospital AP HP Paris 7 Diderot, Clichy, France
    Cancer Res 69:4260-9. 2009
    ..In summary, acquired resistance to PEP005 was associated with expression of EMT markers and activates the ET-1/ETR-A cell signaling...
  29. doi request reprint Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer
    Ghassan El Maalouf
    Department of Medical Oncology, Service inter hospitalier de cancérologie Bichat Beaujon, Beaujon University Hospital, Hopital Beaujon, 100 Boulevard du General Leclerc, 92118 Clichy Cedex, France
    Cancer Treat Rev 35:167-74. 2009
    ....
  30. ncbi request reprint Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas
    Cindy Neuzillet
    INSERM U728 and U773 and Department of Medical Oncology, Beaujon University Hospital AP HP PRES Paris 7 Diderot, 100 Boulevard du General Leclerc, Clichy, France
    Oncotarget 5:78-94. 2013
    ..We also summarize key preclinical and clinical data on the role of TGF-β as a target for therapeutic intervention in PDAC and HCC, and explore perspectives to optimize TGF-β inhibition therapy. ..
  31. doi request reprint Reports of clinical benefit of plitidepsin (Aplidine), a new marine-derived anticancer agent, in patients with advanced medullary thyroid carcinoma
    Christophe Le Tourneau
    Department of Medical Oncology, Beaujon University Hospital, Clichy, France
    Am J Clin Oncol 33:132-6. 2010
    ..To assess clinical benefit of plitidepsin (Aplidine) in patients with advanced medullary thyroid carcinoma (MTC)...
  32. doi request reprint Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors
    Frédérique Maire
    Pôle des Maladies de l Appareil Digestif, Service de Gastroentérologie Pancréatologie, Hopital Beaujon, Clichy, France
    Neuroendocrinology 90:67-72. 2009
    ..Preliminary studies have reported interesting results with temozolomide in patients with DET...
  33. doi request reprint Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer
    Nathalie Théou-Anton
    Department of Pharmacy, Beaujon University Hospital Paris 7, Hopital Beaujon, Clichy, France
    Drug Saf 32:717-34. 2009
    ..Current oral formulations allow physicians to modulate dosages (between 25 and 50 mg/day) and/or schedules (4 weeks on, 2 weeks off or continuous administration) to optimize the benefit-risk profile of sunitinib in individual patients...
  34. ncbi request reprint Molecular basis for sunitinib efficacy and future clinical development
    Sandrine Faivre
    Service Inter Hospitalier de Cancérologie SIHC Beaujon Bichat and RayLab, Hopital Beaujon, APHP and Denis Diderot University, 100 Boulevard du General Leclerc, 92118 Clichy Cedex, France
    Nat Rev Drug Discov 6:734-45. 2007
    ....
  35. doi request reprint Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells
    Maria Serova
    Institut National de la Sante et de la Recherche Medicale U728 RAYLAB and Department of Medical Oncology, Beaujon University Hospital, Clichy, France
    Mol Cancer Ther 7:915-22. 2008
    ..This study supports ongoing efforts targeting PKC isoforms in cancer therapy with PEP005 alone and in combination with other cytotoxic agents...
  36. doi request reprint Pure and mixed fibrolamellar hepatocellular carcinomas differ in natural history and prognosis after complete surgical resection
    Gabriel G Malouf
    Department of Medical Oncology, Beaujon University Hospital, Clichy, France
    Cancer 118:4981-90. 2012
    ..The purpose of the current study was to describe pure and mixed fibrolamellar hepatocellular carcinoma (FL-HCC)...
  37. doi request reprint [PI3K-AKT-mTOR pathway and cancer]
    Laetitia Coutte
    Hopital Beaujon, service interhospitalier de cancérologie, 100, boulevard du General Leclerc, 92118 Clichy Cedex, France
    Bull Cancer 99:173-80. 2012
    ..In the future, predictive factors of response need to be identified; patient selection and associations with chemotherapy or with other targeted therapies should be explored...
  38. ncbi request reprint New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors
    Sandrine Faivre
    Department of Medical Oncology, Hopital Beaujon, Clichy Cedex, Clichy, France
    Semin Oncol 33:407-20. 2006
    ..In this review, we will use the most recent preclinical and clinical data to describe this emerging paradigm for anticancer therapy involving targeting multiple signaling pathways with tyrosine or serine/threonine kinase inhibitors...
  39. ncbi request reprint The role of integrins in colorectal cancer
    Christophe Le Tourneau
    Service inter hospitalier de cancérologie, Bichat Beaujon Beaujon University Hospital, Clichy, France
    Oncology (Williston Park) 21:21-4. 2007
    ..Integrin inhibition alone and with other targeted therapeutic approaches should be further investigated in clinical trials in patients with colorectal cancer...
  40. doi request reprint MEK in cancer and cancer therapy
    Cindy Neuzillet
    INSERM U728 and Department of Medical Oncology, Beaujon University Hospital, AP HP PRES, Paris 7 Diderot, 100 Boulevard du General Leclerc, 92110 Clichy, France Department of Gastroenterology and Pancreatology, Beaujon University Hospital, AP HP PRES, Paris 7 Diderot, 100 Boulevard du General Leclerc, 92110 Clichy, France
    Pharmacol Ther 141:160-71. 2014
    ..We also highlight the known mechanisms of resistance to MEKi and emerging strategies to overcome it. ..
  41. doi request reprint Stromal expression of SPARC in pancreatic adenocarcinoma
    Cindy Neuzillet
    Department of Medical Oncology INSERM U728 PRES Paris 7 Diderot, Beaujon University Hospital, Assistance Publique Hopitaux de Paris, 100 Boulevard du General Leclerc, 92110, Clichy la Garenne, France
    Cancer Metastasis Rev 32:585-602. 2013
    ....
  42. ncbi request reprint Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines
    Nasredine Aissat
    Department of Experimental Pharmacology RayLab and Medical Oncology, Beaujon University Hospital, AP HP, Clichy, France
    Cancer Chemother Pharmacol 62:305-13. 2008
    ..This study aimed to evaluate molecular and cellular effects of rapamycin in a panel of cell lines either as single agent or in combination with cytotoxics commonly used in HNSCC...
  43. doi request reprint Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study
    Sandrine Faivre
    Beaujon University Hospital, Clichy, France
    Lancet Oncol 10:794-800. 2009
    ..In this open-label, multicentre, phase II trial done in Europe and Asia, sunitinib, a multitargeted tyrosine-kinase inhibitor with anti-angiogenic properties, was assessed in patients with advanced unresectable HCC...
  44. doi request reprint Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignancies
    Sandrine Faivre
    Department of Medicine, Gustave Roussy Institute, Villejuif, France
    Eur J Cancer 44:674-82. 2008
    ..Promising antitumour activity was observed in patients with platinum-pretreated lung cancer...
  45. ncbi request reprint Lessons learned in the development of targeted therapy for malignant gliomas
    Antonio M P Omuro
    Groupe Hospitalier Pitie Salpetriere Federation de Neurologie Mazarin 47, Bd de l Hopital, 75661 Paris Cedex 13, France
    Mol Cancer Ther 6:1909-19. 2007
    ....
  46. ncbi request reprint Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors
    Catherine Delbaldo
    Department of Medical Oncology, Beaujon University Hospital, Clichy, France
    Invest New Drugs 26:35-43. 2008
    ..Etaracizumab was well-tolerated at doses up to 6 mg/kg with no evidence of immunogenicity. The safety profile of etaracizumab warrants further exploration in ongoing phase I/II trials...
  47. pmc Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potential
    Catherine Delbaldo
    Department of Medical Oncology, Univ Paris Diderot, Sorbonne Paris Cité, INSERM U728, and Beaujon and Louis Mourier University Hospital Assistance Publique Hopitaux de Paris, Paris 7 Diderot, Clichy, France
    Ther Adv Med Oncol 4:9-18. 2012
    ..These recent data provide hope for patients with well-differentiated pancreatic neuroendocrine tumors and will change standards of care in this disease...
  48. doi request reprint Prognostic value of the chemokine receptor CXCR4 and epithelial-to-mesenchymal transition in patients with squamous cell carcinoma of the mobile tongue
    Sebastien Albert
    INSERM U728, RayLab, and Departments of Medical Oncology, Beaujon University Hospital AP HP Paris 7 Diderot, Clichy, France
    Oral Oncol 48:1263-71. 2012
    ....
  49. ncbi request reprint [Irinotecan and liver dysfunctions]
    Marie Paule Sablin
    Service inter hospitalier de cancérologie Bichat Beaujon, Hopital Beaujon, 100 Boulevard du General Leclerc, 92118 Clichy Cedex, France
    Therapie 62:111-5. 2007
    ..In addition, gene polymorphism of UGT1A1 was shown to be associated with a higher risk of toxicity. However, studies are still required to optimise the use of irinotecan in patients with liver dysfunctions...
  50. pmc Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study
    Eric Raymond
    Service inter hospitalier de cancérologie, Beaujon University Hospital, Clichy
    J Clin Oncol 26:4659-65. 2008
    ..To evaluate the safety and the efficacy of imatinib in recurrent malignant gliomas...
  51. ncbi request reprint Could we expect to improve survival in small cell lung cancer?
    Ghassan El Maalouf
    Department of Medical Oncology, Hopital Beaujon, 100 Boulevard du General Leclerc, 92110 Clichy, France
    Lung Cancer 57:S30-4. 2007
    ..Although further follow-up of patients in this trial is necessary to define response durability and survival, results so far have led to the initiation of phase III trials of pemetrexed-based regimens in ES-SCLC...
  52. pmc Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST)
    Christophe Le Tourneau
    Department of Medical Oncology Hôpital Beaujon, Clichy, France
    Ther Clin Risk Manag 3:341-8. 2007
    ..Clinical trials investigating sunitinib in other tumor types are ongoing...